Symbol not found

:PRVL   00:00AM GMT
0.00
0.00 (0.00%)
Products, Regulatory

Prevail Therapeutics Announces First Patient Dosed In Phase 1/2 Proclaim Clinical Trial Evaluating PR006 For The Treatment Of Frontotemporal Dementia Patients With GRN Mutations

Published: 12/11/2020 12:11 GMT
(PRVL) - Prevail Therapeutics Announces First Patient Dosed in Phase 1/2 Proclaim Clinical Trial Evaluating Pr006 for the Treatment of Frontotemporal Dementia Patients With Grn Mutations.
Prevail Therapeutics Inc - Anticipates It Will Provide a Biomarker and Safety Analysis on Subset of Patients Enrolled in Proclaim Trial in 2021.